



Webinar

New Technologies for Neglected Diseases: What is Likely to Come out of the Pipeline, What is Missing, and What Will it Cost?

Gavin Yamey

20 November 2018

Q&A Session with the Participants

15:59:53

From Julián Andrés Molina Menjura to all panellists: Hola. Buen día.

15:59:59

From Julián Andrés Molina Menjura to all panellists: Good morning here.

16:00:04

From Julián Andrés Molina Menjura to all panellists: From Bogotá, Colombia.

16:01:02

From Robert Terry to all panellists: Hello Gavin!

16:33:43

From Gavin Yamey to all panellists: Hi Rob!

16:34:00

From Robert Terry: Thanks for that.

16:38:07

From Renee Holt to all panellists: Let's get into the discussion of why so many products for TB. What is your opinion? Are there too many? What diseases, in your opinion, should be receiving more funding than they currently are for the greatest global health impact?

16:38:31

From Renee Holt to all panellists: Sorry, that is GLOBAL health impact.

16:38:34

From Shailly Gupta to all panellists: sorry that was a mistake.

16:38:40

From Shailly Gupta to all panellists: I do not have a Question.

16:39:05

From Sebastien Morin to all panellists: Yes. This was a mistake. I have not raised my hand, sorry.

16:43:05

From Global Health Centre IHEID: thanks Shailly, Sebastien, all clear now.

16:44:13

From Global Health Centre IHEID: the two products I mentioned are fexinidazole for sleeping sickness from DNDi (recent EMA positive opinion), pretomanid from Global Alliance for TB (unclear when launching but relatively soon, NCE for TB).

16:48:06

From Janis Lazdins to all panellists: Does the model tells anything on the size of discovery and preclinical research that current predicted funding can sustain?

16:48:33

From Global Health Centre IHEID to David Branigan and all panellists: Hi David, did you raise your hand?

17:01:48

From Renee Holt to all panellists: Thank you. Excellent webinar!

17:02:16

From Aparna Ananth to all panellists: Will a recording of this webinar be made available?

17:02:21

From Gavin Yamey to all panellists: Thanks to everyone for joining, I enjoyed it immensely.